Targeting RAS -mutant Cancers: Is ERK the Key?

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations · Full text

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 2.9K citations

Oncology, Braf-mutated Metastatic Melanoma, Melanoma +6

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.6K citations · Full text